Tendon injuries—ranging from tendinopathy (overuse inflammation) to partial or complete tears—occur commonly in athletes and active individuals. Treatment varies by severity and aims to restore strength, prevent re-injury, and return to sport safely.
Acute management follows RICE (rest, ice, compression, elevation) to reduce swelling and pain. NSAIDs (ibuprofen, naproxen) reduce inflammation, though some debate their use in early healing. Immobilisation via brace, sling, or cast protects minor strains and allows initial healing, typically 1–3 weeks depending on severity. Physiotherapy is central: eccentric-loading exercises (lengthening under load) are especially effective for chronic tendinopathy, improving strength and reducing pain. Corticosteroid injections around the tendon (not into it, which risks rupture) may provide short-term relief but should be combined with rehabilitation. Shock-wave therapy (extracorporeal shock-wave therapy, ESWT) shows moderate evidence for some tendon conditions. Complete tears or severe injuries may require surgical repair followed by progressive rehabilitation over 3–6 months.
Platelet-rich plasma (PRP) injections are gaining popularity for tendinopathy; blood is processed to concentrate platelets, then injected to stimulate healing. Evidence is accumulating but remains mixed—some studies show benefit, others are equivocal. Manual therapy, massage, and soft-tissue mobilisation complement formal physio. Prolotherapy (repeated dextrose or other irritant injections) aims to trigger tissue repair; evidence is limited. Topical NSAIDs and anti-inflammatory patches are used for comfort. Some athletes use acupuncture alongside rehabilitation with modest reported benefit.
Stem-cell therapies—particularly bone-marrow-derived mesenchymal stem cells injected into damaged tendons—are being studied for chronic tendinopathy and partial tears. Early trials suggest potential for reducing inflammation and promoting tissue regeneration. These remain investigational and are not yet standard care outside clinical trials. Candidacy typically requires failed conservative treatment and imaging confirmation of pathology. See regenerative approaches for tendon injuries and evaluation criteria.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| RICE, NSAIDs & immobilisation | Standard | Strong | €5–100 | Low | Acute phase 1–3 weeks |
| Eccentric-loading physiotherapy | Standard | Strong | €50–100 per session | Low | Ongoing; 8–12 weeks improvement |
| Corticosteroid injections (peritendinous) | Standard | Moderate | €150–300 | Medium | Few days; effects 2–8 weeks |
| Extracorporeal shock-wave therapy (ESWT) | Standard | Moderate | €300–600 per course | Low | None; mild soreness possible |
| Surgical repair (for complete tears) | Standard | Strong | €5,000–15,000 | High | 3–6 months rehabilitation |
| PRP injections | Alternative | Moderate | €600–1,500 | Medium | Few days; multiple injections may be needed |
| Prolotherapy | Alternative | Limited | €300–800 per session | Medium | Few days; series of injections |
| Stem-cell therapy | Regenerative | Investigational | €4,000–14,000 | Medium | 2–4 weeks; clinical trials underway |
Eccentric loading is evidence-based for chronic tendinopathy and often succeeds without additional intervention, though results take 8–12 weeks and require discipline. For acute tears or if conservative care fails, injections or surgery may be needed, but eccentric training remains part of recovery regardless.
Peritendinous corticosteroid injections—placed around but not into the tendon—can provide relief combined with physiotherapy. Injections directly into the tendon carry a small rupture risk and are generally avoided. Always ensure injection is guided and performed by experienced practitioners.
Both are investigational. PRP, using your own blood platelets, has more clinical data but mixed results. Stem cells may offer broader regenerative potential but are less studied for tendons. Neither is standard care; choice depends on access, cost, and specialist recommendation.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment